JP2016502973A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502973A5 JP2016502973A5 JP2015545855A JP2015545855A JP2016502973A5 JP 2016502973 A5 JP2016502973 A5 JP 2016502973A5 JP 2015545855 A JP2015545855 A JP 2015545855A JP 2015545855 A JP2015545855 A JP 2015545855A JP 2016502973 A5 JP2016502973 A5 JP 2016502973A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- heterocyclyl
- heteroaryl
- compound according
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 53
- 125000000623 heterocyclic group Chemical group 0.000 claims 36
- 125000001072 heteroaryl group Chemical group 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 9
- 125000001153 fluoro group Chemical group F* 0.000 claims 9
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 claims 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims 7
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 101100273648 Mus musculus Ccna2 gene Proteins 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- -1 pyridin-1-yl Chemical group 0.000 claims 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 4
- 125000001246 bromo group Chemical group Br* 0.000 claims 4
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 claims 4
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 150000001204 N-oxides Chemical class 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 239000011593 sulfur Substances 0.000 claims 3
- 239000002132 β-lactam antibiotic Substances 0.000 claims 3
- 229940124586 β-lactam antibiotics Drugs 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 150000001336 alkenes Chemical group 0.000 claims 2
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims 2
- 229960003644 aztreonam Drugs 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 claims 2
- URYYVOIYTNXXBN-UPHRSURJSA-N cyclooctene Chemical compound C1CCC\C=C/CC1 URYYVOIYTNXXBN-UPHRSURJSA-N 0.000 claims 2
- 239000004913 cyclooctene Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 150000002923 oximes Chemical class 0.000 claims 2
- AEBWATHAIVJLTA-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalene Chemical compound C1CCC2CCCC21 AEBWATHAIVJLTA-UHFFFAOYSA-N 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 229930186147 Cephalosporin Natural products 0.000 claims 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 125000002015 acyclic group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- JSMRMEYFZHIPJV-UHFFFAOYSA-N bicyclo[2.1.1]hexane Chemical compound C1C2CC1CC2 JSMRMEYFZHIPJV-UHFFFAOYSA-N 0.000 claims 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 claims 1
- GNTFBMAGLFYMMZ-UHFFFAOYSA-N bicyclo[3.2.2]nonane Chemical compound C1CC2CCC1CCC2 GNTFBMAGLFYMMZ-UHFFFAOYSA-N 0.000 claims 1
- WMRPOCDOMSNXCQ-UHFFFAOYSA-N bicyclo[3.3.2]decane Chemical compound C1CCC2CCCC1CC2 WMRPOCDOMSNXCQ-UHFFFAOYSA-N 0.000 claims 1
- 125000005621 boronate group Chemical group 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 229940124587 cephalosporin Drugs 0.000 claims 1
- 150000001780 cephalosporins Chemical class 0.000 claims 1
- NNBZCPXTIHJBJL-AOOOYVTPSA-N cis-decalin Chemical compound C1CCC[C@H]2CCCC[C@H]21 NNBZCPXTIHJBJL-AOOOYVTPSA-N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 claims 1
- 239000004914 cyclooctane Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- BNRNAKTVFSZAFA-UHFFFAOYSA-N hydrindane Chemical compound C1CCCC2CCCC21 BNRNAKTVFSZAFA-UHFFFAOYSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 claims 1
- 229940049954 penicillin Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- NNBZCPXTIHJBJL-UHFFFAOYSA-N trans-decahydronaphthalene Natural products C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 claims 1
- NNBZCPXTIHJBJL-MGCOHNPYSA-N trans-decalin Chemical compound C1CCC[C@@H]2CCCC[C@H]21 NNBZCPXTIHJBJL-MGCOHNPYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261734900P | 2012-12-07 | 2012-12-07 | |
| US61/734,900 | 2012-12-07 | ||
| US201361783238P | 2013-03-14 | 2013-03-14 | |
| US61/783,238 | 2013-03-14 | ||
| PCT/US2013/073428 WO2014089365A1 (en) | 2012-12-07 | 2013-12-05 | Beta-lactamase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018114967A Division JP2018184409A (ja) | 2012-12-07 | 2018-06-15 | ベータ−ラクタマーゼ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016502973A JP2016502973A (ja) | 2016-02-01 |
| JP2016502973A5 true JP2016502973A5 (enExample) | 2016-12-01 |
| JP6403219B2 JP6403219B2 (ja) | 2018-10-10 |
Family
ID=50884012
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545855A Active JP6403219B2 (ja) | 2012-12-07 | 2013-12-05 | ベータ−ラクタマーゼ阻害剤 |
| JP2018114967A Pending JP2018184409A (ja) | 2012-12-07 | 2018-06-15 | ベータ−ラクタマーゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018114967A Pending JP2018184409A (ja) | 2012-12-07 | 2018-06-15 | ベータ−ラクタマーゼ阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (6) | US9422314B2 (enExample) |
| EP (2) | EP3922635A1 (enExample) |
| JP (2) | JP6403219B2 (enExample) |
| KR (1) | KR102147420B1 (enExample) |
| CN (1) | CN105026407B (enExample) |
| AU (1) | AU2013355110B2 (enExample) |
| BR (1) | BR112015013123B1 (enExample) |
| CA (1) | CA2893943C (enExample) |
| ES (1) | ES2878118T3 (enExample) |
| HR (1) | HRP20210879T1 (enExample) |
| IL (1) | IL239212B (enExample) |
| PL (1) | PL2928898T3 (enExample) |
| PT (1) | PT2928898T (enExample) |
| RU (1) | RU2654692C2 (enExample) |
| WO (1) | WO2014089365A1 (enExample) |
| ZA (1) | ZA201504200B (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3412676T3 (pl) | 2010-08-10 | 2021-04-06 | Melinta Therapeutics, Inc. | Cykliczne pochodne estrowe kwasu boronowego, sposób otrzymywania oraz ich zastosowania terapeutyczne |
| WO2013033461A1 (en) | 2011-08-31 | 2013-03-07 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
| US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| PL2928898T3 (pl) * | 2012-12-07 | 2021-10-25 | VenatoRx Pharmaceuticals, Inc. | Inhibitory beta-laktamaz |
| US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| EP2941246A4 (en) * | 2013-01-04 | 2016-12-21 | Rempex Pharmaceuticals Inc | BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES |
| KR20150103270A (ko) | 2013-01-04 | 2015-09-09 | 렘펙스 파머수티클스 인코퍼레이티드 | 보론산 유도체 및 그의 치료적 용도 |
| ES2730013T3 (es) | 2013-01-10 | 2019-11-07 | Venatorx Pharmaceuticals Inc | Inhibidores de betalactamasa |
| US9944658B2 (en) | 2013-03-14 | 2018-04-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US9687497B1 (en) | 2014-05-05 | 2017-06-27 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
| EP3140310B1 (en) | 2014-05-05 | 2019-08-07 | Rempex Pharmaceuticals, Inc. | Synthesis of boronate salts and uses thereof |
| AU2015264418A1 (en) | 2014-05-19 | 2016-11-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US20150361108A1 (en) * | 2014-06-11 | 2015-12-17 | VenatoRx Pharmaceuticals, Inc. | Orally bioavailable beta-lactamase inhibitors |
| US9511142B2 (en) | 2014-06-11 | 2016-12-06 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| ES2874579T3 (es) | 2014-06-11 | 2021-11-05 | Venatorx Pharmaceuticals Inc | Inhibidores de betalactamasa |
| US10206937B2 (en) | 2014-07-01 | 2019-02-19 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| WO2016081297A1 (en) | 2014-11-18 | 2016-05-26 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| US10364257B2 (en) | 2014-12-19 | 2019-07-30 | Rempex Pharmaceuticals, Inc. | Apparatus and continuous flow process for production of boronic acid derivatives |
| WO2016102672A2 (en) * | 2014-12-23 | 2016-06-30 | Bergenbio As | Pharmaceutically active compounds |
| US20180051041A1 (en) | 2015-03-17 | 2018-02-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CN108472284A (zh) | 2015-09-11 | 2018-08-31 | 维纳拓尔斯制药公司 | β-内酰胺酶抑制剂 |
| WO2017100537A1 (en) | 2015-12-10 | 2017-06-15 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| CN105801610B (zh) * | 2016-04-19 | 2018-05-18 | 武汉维舜医药科技有限公司 | 新型广谱β-内酰胺酶抑制剂 |
| MY196909A (en) | 2016-06-30 | 2023-05-09 | Qpex Biopharma Inc | Boronic acid derivatives and therapeutic uses thereof |
| US10889600B2 (en) | 2016-08-04 | 2021-01-12 | VenatoRx Pharmaceuticals, Inc. | Boron-containing compounds |
| GB201613946D0 (en) | 2016-08-15 | 2016-09-28 | Univ Oslo | Compounds |
| PL3592362T3 (pl) * | 2017-03-06 | 2025-06-23 | VenatoRx Pharmaceuticals, Inc. | Postacie stałe i kompozycje skojarzone zawierające inhibitor beta-laktamaz i ich zastosowania |
| WO2018199291A1 (ja) * | 2017-04-28 | 2018-11-01 | 大日本住友製薬株式会社 | ヘテロ環誘導体 |
| GB201708002D0 (en) | 2017-05-18 | 2017-07-05 | Univ Oxford Innovation Ltd | ß-Lactamase inhibitors |
| US11267826B2 (en) | 2017-05-26 | 2022-03-08 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| EP3630782A4 (en) * | 2017-05-26 | 2021-03-03 | Venatorx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| EP3694864B1 (en) | 2017-10-11 | 2025-03-05 | Qpex Biopharma, Inc. | Boronic acid derivatives and synthesis thereof |
| US11999757B2 (en) * | 2017-11-01 | 2024-06-04 | Melinta Subsidiary Corp. | Synthesis of boronate ester derivatives and uses thereof |
| AU2019256351B2 (en) | 2018-04-20 | 2024-02-29 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CN118638140A (zh) | 2018-04-27 | 2024-09-13 | 住友制药株式会社 | 氧代取代化合物 |
| EP3802551A4 (en) * | 2018-05-25 | 2022-03-02 | Venatorx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| WO2020056048A1 (en) | 2018-09-12 | 2020-03-19 | VenatoRx Pharmaceuticals, Inc. | Combination compositions comprising a beta-lactamase inhibitor |
| EP3886798B1 (en) | 2018-11-29 | 2026-01-28 | Venatorx Pharmaceuticals, Inc. | Combination compositions comprising a beta-lactamase inhibitor and uses thereof |
| AU2020256179A1 (en) * | 2019-04-02 | 2021-11-18 | VenatoRx Pharmaceuticals, Inc. | Solid forms of an orally-delivered beta-lactamase inhibitor and uses thereof |
| JP7550421B2 (ja) * | 2019-10-25 | 2024-09-13 | 住友ファーマ株式会社 | オキソ置換化合物からなる医薬 |
| WO2021079984A1 (ja) | 2019-10-25 | 2021-04-29 | 大日本住友製薬株式会社 | 新規置換縮環型化合物 |
| US11058695B2 (en) * | 2019-11-08 | 2021-07-13 | Myongji University Industry And Academia Cooperation Foundation | Inhibitor of carbapenem-hydrolyzing class D beta-lactamases |
| WO2021108023A1 (en) | 2019-11-26 | 2021-06-03 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| US12552815B2 (en) | 2020-05-05 | 2026-02-17 | Qpex Biopharma, Inc. | Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof |
| US12590108B2 (en) | 2020-08-20 | 2026-03-31 | Phaeno Therapeutics Co., Ltd | Boracic acid compound |
| US12606573B2 (en) | 2020-10-07 | 2026-04-21 | VenatoRx Pharmaceuticals, Inc. | Process for boron-containing compounds |
| TW202228720A (zh) * | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
| WO2022187362A1 (en) * | 2021-03-02 | 2022-09-09 | Case Western Reserve University | Β-lactamase inhibitors and uses thereof |
| EP4324837A4 (en) * | 2021-04-13 | 2024-10-16 | Tuojie Biotech (Shanghai) Co., Ltd. | Boric acid derivative acting as beta-lactamase inhibitor |
| CN115490713A (zh) * | 2021-06-17 | 2022-12-20 | 上海济煜医药科技有限公司 | 硼酸衍生物及其制备方法和应用 |
| WO2023155869A1 (zh) * | 2022-02-18 | 2023-08-24 | 辉诺生物医药科技（杭州）有限公司 | 新的硼酸类化合物的晶型及其制备方法 |
| GB202306835D0 (en) | 2023-05-09 | 2023-06-21 | Adjutec Pharma As | Therapy |
| TW202529745A (zh) | 2023-11-21 | 2025-08-01 | 美商維納拓爾斯製藥公司 | 經口遞送之β-內醯胺酶抑制劑之檸檬酸鹽配位錯合物及其用途 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE41109B1 (en) | 1974-04-20 | 1979-10-24 | Beecham Group Ltd | Novel -lactam antibiotic from streptomyces clavuligerus |
| IT1283467B1 (it) * | 1996-07-19 | 1998-04-21 | Menarini Farma Ind | Derivati di cicloalcani 1,2 sostituiti come inibitori della trombina, procedimento per la loro preparazione e loro impiego in formulazioni |
| KR20020088406A (ko) | 1999-09-17 | 2002-11-27 | 애보트 게엠베하 운트 콤파니 카게 | 치료제로서의 피라졸로피리미딘 |
| US7271186B1 (en) | 2002-12-09 | 2007-09-18 | Northwestern University | Nanomolar β-lactamase inhibitors |
| WO2005004799A2 (en) | 2003-06-10 | 2005-01-20 | Fulcrum Pharmaceuticals, Inc. | β-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF |
| RS53259B (sr) | 2004-03-30 | 2014-08-29 | Millennium Pharmaceuticals Inc. | Sinteza bortezomiba |
| CN1965838A (zh) | 2005-11-17 | 2007-05-23 | 李海超 | 含头孢匹胺和β－内酰胺酶抑制剂的药物组合物 |
| ATE529111T1 (de) | 2005-12-07 | 2011-11-15 | Basilea Pharmaceutica Ag | Nützliche monobactam-antibiotika |
| CN101129382B (zh) | 2006-08-25 | 2013-12-25 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和缓冲组分的抗生素复方 |
| CN101983203A (zh) | 2007-11-13 | 2011-03-02 | 诺瓦提斯国际药物有限公司 | β-内酰胺酶抑制剂 |
| US20100120715A1 (en) | 2007-11-13 | 2010-05-13 | Burns Christopher J | Beta-lactamase inhibitors |
| MY162532A (en) | 2008-01-18 | 2017-06-15 | Merck Sharp & Dohme | Beta-lactamase inhibitors |
| US20100292185A1 (en) | 2009-05-12 | 2010-11-18 | Burns Christopher J | Beta-lactamase inhibitors |
| KR20130031233A (ko) | 2009-07-28 | 2013-03-28 | 아나코르 파마슈티칼스 인코포레이티드 | 삼치환된 붕소 함유 분자 |
| PL3412676T3 (pl) | 2010-08-10 | 2021-04-06 | Melinta Therapeutics, Inc. | Cykliczne pochodne estrowe kwasu boronowego, sposób otrzymywania oraz ich zastosowania terapeutyczne |
| MX362683B (es) | 2011-07-26 | 2019-01-31 | Wockhardt Ltd | Composiciones farmacéuticas que comprenden antibiótico de beta-lactama, sulbactama e inhibidor de beta-lactamasa. |
| JP6211418B2 (ja) | 2011-09-04 | 2017-10-11 | 株式会社糖鎖工学研究所 | 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物 |
| WO2013053372A1 (en) | 2011-10-13 | 2013-04-18 | Therabor Pharmaceuticals | Boronic acid inhibitors of beta-lactamases |
| KR101288157B1 (ko) | 2011-12-07 | 2013-07-19 | 백병하 | 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제 |
| US9688702B2 (en) | 2011-12-22 | 2017-06-27 | Ares Trading | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
| EP2814483A2 (en) | 2012-02-15 | 2014-12-24 | Rempex Pharmaceuticals, Inc. | Methods of treating bacterial infections |
| BR112015012909A2 (pt) | 2012-12-03 | 2017-07-11 | Hoffmann La Roche | compostos de ácido borônico de triazol substituído |
| PL2928898T3 (pl) * | 2012-12-07 | 2021-10-25 | VenatoRx Pharmaceuticals, Inc. | Inhibitory beta-laktamaz |
| US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| EP2941246A4 (en) | 2013-01-04 | 2016-12-21 | Rempex Pharmaceuticals Inc | BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES |
| KR20150103270A (ko) | 2013-01-04 | 2015-09-09 | 렘펙스 파머수티클스 인코퍼레이티드 | 보론산 유도체 및 그의 치료적 용도 |
| ES2730013T3 (es) | 2013-01-10 | 2019-11-07 | Venatorx Pharmaceuticals Inc | Inhibidores de betalactamasa |
| US9944658B2 (en) | 2013-03-14 | 2018-04-17 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| WO2015051101A1 (en) | 2013-10-02 | 2015-04-09 | Cubist Pharmaceuticals, Inc. | B-lactamase inhibitor picoline salt |
| WO2015157618A1 (en) | 2014-04-11 | 2015-10-15 | The Texas A&M University System | Novel inhibitors of the new delhi metallo beta lactamase (ndm-1) |
| AU2015264418A1 (en) | 2014-05-19 | 2016-11-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US9511142B2 (en) | 2014-06-11 | 2016-12-06 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US20150361108A1 (en) | 2014-06-11 | 2015-12-17 | VenatoRx Pharmaceuticals, Inc. | Orally bioavailable beta-lactamase inhibitors |
| ES2874579T3 (es) * | 2014-06-11 | 2021-11-05 | Venatorx Pharmaceuticals Inc | Inhibidores de betalactamasa |
| US20150361107A1 (en) * | 2014-06-11 | 2015-12-17 | VenatoRx Pharmaceuticals, Inc. | Orally bioavailable beta-lactamase inhibitors |
| WO2016035846A1 (ja) | 2014-09-04 | 2016-03-10 | 塩野義製薬株式会社 | カテコール基を有するセファロスポリン類を含有する製剤 |
| US10364257B2 (en) | 2014-12-19 | 2019-07-30 | Rempex Pharmaceuticals, Inc. | Apparatus and continuous flow process for production of boronic acid derivatives |
| CN108472284A (zh) | 2015-09-11 | 2018-08-31 | 维纳拓尔斯制药公司 | β-内酰胺酶抑制剂 |
| WO2017100537A1 (en) | 2015-12-10 | 2017-06-15 | VenatoRx Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| CN105801610B (zh) | 2016-04-19 | 2018-05-18 | 武汉维舜医药科技有限公司 | 新型广谱β-内酰胺酶抑制剂 |
| US10889600B2 (en) | 2016-08-04 | 2021-01-12 | VenatoRx Pharmaceuticals, Inc. | Boron-containing compounds |
| PL3592362T3 (pl) | 2017-03-06 | 2025-06-23 | VenatoRx Pharmaceuticals, Inc. | Postacie stałe i kompozycje skojarzone zawierające inhibitor beta-laktamaz i ich zastosowania |
| EP3630782A4 (en) | 2017-05-26 | 2021-03-03 | Venatorx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| US11267826B2 (en) | 2017-05-26 | 2022-03-08 | VenatoRx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
| WO2019118358A1 (en) | 2017-12-11 | 2019-06-20 | VenatoRx Pharmaceuticals, Inc. | Hepatitis b capsid assembly modulators |
| EP3802551A4 (en) | 2018-05-25 | 2022-03-02 | Venatorx Pharmaceuticals, Inc. | Penicillin-binding protein inhibitors |
-
2013
- 2013-12-05 PL PL13861198T patent/PL2928898T3/pl unknown
- 2013-12-05 WO PCT/US2013/073428 patent/WO2014089365A1/en not_active Ceased
- 2013-12-05 PT PT138611983T patent/PT2928898T/pt unknown
- 2013-12-05 US US14/649,527 patent/US9422314B2/en active Active
- 2013-12-05 AU AU2013355110A patent/AU2013355110B2/en active Active
- 2013-12-05 JP JP2015545855A patent/JP6403219B2/ja active Active
- 2013-12-05 RU RU2015126912A patent/RU2654692C2/ru active
- 2013-12-05 EP EP21164891.0A patent/EP3922635A1/en not_active Withdrawn
- 2013-12-05 CA CA2893943A patent/CA2893943C/en active Active
- 2013-12-05 HR HRP20210879TT patent/HRP20210879T1/hr unknown
- 2013-12-05 KR KR1020157017875A patent/KR102147420B1/ko active Active
- 2013-12-05 BR BR112015013123-9A patent/BR112015013123B1/pt active IP Right Grant
- 2013-12-05 ES ES13861198T patent/ES2878118T3/es active Active
- 2013-12-05 CN CN201380072524.5A patent/CN105026407B/zh active Active
- 2013-12-05 EP EP13861198.3A patent/EP2928898B1/en active Active
- 2013-12-06 US US14/099,633 patent/US8912169B2/en active Active
-
2015
- 2015-06-04 IL IL23921215A patent/IL239212B/en active IP Right Grant
- 2015-06-10 ZA ZA2015/04200A patent/ZA201504200B/en unknown
-
2016
- 2016-07-18 US US15/212,959 patent/US9828391B2/en active Active
-
2017
- 2017-10-18 US US15/787,224 patent/US10214547B2/en active Active
-
2018
- 2018-06-15 JP JP2018114967A patent/JP2018184409A/ja active Pending
-
2019
- 2019-01-02 US US16/238,363 patent/US10669290B2/en active Active
-
2024
- 2024-08-29 US US18/819,935 patent/US20250236632A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015126912A (ru) | Ингибиторы бета-лактамаз | |
| JP2016506419A5 (enExample) | ||
| CA2979537C (en) | Piperazine carbamates and methods of making and using same | |
| JP5242857B2 (ja) | Ｓｙｋ阻害剤としてのアミノピリミジン類 | |
| NZ603427A (en) | 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) | |
| JP2016515560A5 (enExample) | ||
| AU2018346597A1 (en) | Inhibiting Ubiquitin Specific Peptidase 30 | |
| RU2012119488A (ru) | Конденсированные азиновые производные для лечения заболеваний, связанных с ацетилхолиновым рецептором | |
| JP2006521359A5 (enExample) | ||
| AU2017279027A1 (en) | Chemical Compounds | |
| AU2019344107B2 (en) | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | |
| WO2015003002A1 (en) | Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof | |
| AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| RU2015135891A (ru) | Новые производные пиразола | |
| JP2015509535A5 (enExample) | ||
| JP2010527983A5 (enExample) | ||
| JP2017529365A5 (enExample) | ||
| DK2966079T1 (da) | Pyridopyrimidin eller pyrimidopyrimidinforbindelse, fremstillingsmetode, pharmaceutisk præparat og anvendelse heraf | |
| CA3256989A1 (en) | COMPOUNDS FOR INHIBITING KIF18A | |
| SG10201907667RA (en) | Morphinan derivative | |
| JP2016532669A5 (enExample) | ||
| JP2013525262A5 (enExample) | ||
| JP2013535414A5 (enExample) | ||
| JP2015500842A5 (enExample) | ||
| CA3063938A1 (en) | Compounds, compositions and methods |